|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
Survival Guide to FDA Inspections: Part 2, Conducting the Audit ? Ready or Not, Here They Come
Author(s)Massoud Lavian, Paul W. Allen
by Massoud Lavian and Paul W. Allen, Clarkston Consulting When an FDA inspection is imminent, it pays to have a plan. Start by getting your papers in order and your facility in a state of good repair. Train a team to manage interaction with inspectors. Coach your employees on how to answer questions. And don't forget to take notes.
Advertisement
Articles in this issue
almost 23 years ago
FDA Launches Major CGMP Reviewalmost 23 years ago
Process Validation: How Much to Do and When to Do Italmost 23 years ago
Biotech Will Recover!almost 23 years ago
GMPs and Pharmaceutical Labelingalmost 23 years ago
Revolutionizing Biologics RegulationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4